Fibroblast growth factor 21, Recombinant, Human (FGF-21)

Article Name:	Fibroblast growth factor 21, Recombinant, Human (FGF-21)
Biozol Catalog Number:	USB-F4212-93A
Supplier Catalog Number:	F4212-93A
Alternative Catalog Number:	USB-F4212-93A-25
Manufacturer:	US Biological
Category:	Molekularbiologie

Human FGF-21 Fibroblast growth factor 21 (FGF-21) is a member of the FGF gene family, which currently contains 22 human members. Based on its structure, it is further classified as an FGF19 subfamily member. This subfamily includes FGF-19, -21, and -23. Like all other FGF subfamilies, FGF-19 subfamily members contain a 120 amino acid (aa) core FGF domain that exhibits a b-trefoil structure (1, 2). Unlike other FGF subfamilies, FGF-19 subfamily members apparently exhibit poor binding to ECM, resulting in highly diffusible molecules (3). The c-DNA for FGF-21 predicts a 209aa polypeptide that contains a 28aa signal sequence and a 181aa mature region (4). Notably, FGF-21, as well as FGF-19 shows limited binding to heparin (4). One potential alternate splice form has been reported. It shows a 43aa substitution for the C-terminal 12aa of the standard form (5). Mature human FGF-21 shows 81% aa identity to mouse FGF-21, and is known to be active on mouse cells (4, 6). The FGF-19 subfamily is considered endocrine in nature. All three subfamily members impact some aspect of metabolism, all three are induced by a nuclear receptor heterodimer that includes RXR, and all three utilize Klotho family members for signal transduction (7, 8, 9). FGF-21 is produced by hepatocytes in response to free fatty acid (FFA) stimulation of a PPARa/RXR dimeric complex. This situation occurs clinically during starvation, or following the ingestion of a high-fat/low-carbohydrate diet. Upon FGF-21 secretion, white adipose tissue is induced to release FFAs from triglyceride stores. Once FFAs reach hepatocytes, they are oxidized and reduced to acetyl-CoA. The acetyl-CoA is recombined into 4-carbon ketone bodies (acetoacetate and b-hydroxybutyrate), released, and transported to peripheral tissues for TCA processing and energy generation. Recombinant human FGF-21, derived from E. coli, consists of amino acids encompassing His29-Ser209, with an N-terminal 5-His tag. It has a predicted molecular mass of approximately 20.2kD. Biological Activity: Measured by its ability to stimulate the proliferation of BaF3 mouse pro-B cells transfected with human FGF RIIIc. The ED50 for this effect is typically 0.06-0.4ug/ml in the presence of rmKlotho-beta. Measured by its ability to stimulate the proliferation of NIH3T3 cells. The ED50 for this effect is typically 0.12-0.6ug/ml in the presence of 5ug/ml of rmKlotho-beta. Storage and Stability: Lyophilized and reconstituted products are stable for 6 months after receipt at -20C. Reconstitute with sterile PBS containing at least 0.1% HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

UniProt:	Q9NSA1
Purity:	97%, as determined by SDS-PAGE and visualized by silver stain. Endotoxin: <1EU/1ug (LAL).
Form:	Supplied as a lyophilized powder in 10mM MES, 50mM sodium sulfate, 0.2mM EDTA, 0.2mM DTT, pH 6.5. Reconstitute with PBS to a concentration of 0.1mg/ml.